By Jeff Overley ( August 21, 2013, 1:50 PM EDT) -- With generic competition looming, Allergan Inc. on Monday released a letter decrying the U.S. Food and Drug Administration's proposal not to require human testing for generic versions of dry-eye medicine Restasis, calling the concept "unnecessary, unjustified and potentially unsafe."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.